Press Releases
01 June 2009
CSL Behring Announces Winners of 2009 Prof. Heimburger Awards
CSL Behring, a global leader in the protein biotherapeutics industry, announced today the five grant winners of the 2009 Prof. Heimburger Awards. The grants of 20,000€ ($26,780 US) each were awarded to young clinicians conducting preclinical and/or clinical research in coagulation. Each project was chosen based on the scientific merit of the proposed initiative.
More.
18 May 2009
ZLB Plasma Changes Name to CSL Plasma
ZLB Plasma has changed its name to CSL Plasma to align more closely with its parent company, CSL Limited. CSL Plasma is one of the world’s largest collectors of human plasma for use in manufacturing life-saving biotherapies. Headquartered in Boca Raton, FL, CSL Plasma operates collection centers throughout the United States and in Germany. It also operates state-of-the-art testing laboratories in Knoxville, TN and Goettingen, Germany, and logistics centers in Indianapolis, IN and Schwalmstadt, Germany.
More.
04 May 2009
Patient Convenience Focus of New Upgrades to HeliTrax System by CSL Behring
Hemophilia A patients and their treatment providers are now better able to manage their condition, thanks to an enhanced HeliTrax™ System from CSL Behring. Patients can now track and record their treatment progress in real time anywhere that internet access is available. By using a password-protected web interface, hemophilia A patients can easily input their treatment data and monitor their condition online even when they are not carrying their handheld electronic diary.
More.
17 April 2009
CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia
In recognition of the World Federation of Hemophilia’s (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating to WFH two (2) million units of factor VIII concentrate (FVIII) each year for the next three (3) years. The donation, the total value of which will be approximately $2 million, will be made using coagulation factor concentrate with a minimum shelf-life of one year.
More.
02 April 2009
CSL Behring to Launch Next GameFaces™ Program Challenge
CSL Behring announced it will hold its next GameFaces™ challenge from April 14 through July 7, 2009. GameFaces is a family-oriented, online initiative for people with hemophilia A. The program is designed to encourage real-life physical activity through a series of customized challenges based on the individual’s age, disease severity and current level of physical activity.
More.
31 March 2009
CSL Behring Seeking Proposals for LEAD Grants to Support Patient Advocacy Efforts
CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
More.
15 March 2009
Rapid Treatment of Hereditary Angioedema Attacks at the Onset of Prodromal Symptoms Decreases Morbidity and Mortality
The importance of recognizing prodromal symptoms and treating acute attacks of hereditary angioedema (HAE) at the onset of these symptoms was highlighted in a survey presented today at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. While symptoms of acute HAE attacks include episodes of edema or swelling in the hands and feet, the face, the abdomen, and/or the larynx, prodromal symptoms, which occur before an attack, are often non-specific and highly-variable, according to study findings. Treatment at the onset of these early symptoms can decrease morbidity and mortality associated with this rare and serious genetic disorder.
More.
15 March 2009
C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute Swelling Attacks Across All Body Sites in Patients with Hereditary Angioedema, According to Study
C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Interim results from the ongoing, prospective, open label
International
Multi-center
Prospective
Angioedema
C1-Inhibitor
Trial (I.M.P.A.C.T. 2), showed a median time to the onset of symptom relief of 16 minutes for laryngeal attacks, 23 minutes for abdominal attacks, 28 minutes for facial attacks and 31 minutes for peripheral attacks, such as attacks in the hands and feet. In total, 57 patients who experienced 640 HAE attacks in any body location were studied.
More.
11 March 2009
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP™
CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP™ is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven years of orphan-drug exclusivity. RiaSTAP was approved by the FDA in January and is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Approval was based on a pivotal phase II prospective, open-label pharmacokinetic (PK) and safety study using maximum clot firmness as a surrogate endpoint for hemostatic efficacy.
More.
11 December 2008
CSL Behring Launches Voice2Voice™ Vivaglobin® Advocacy Program for New Patients and Caregivers
CSL Behring, a worldwide leader in developing immunoglobulin therapies, announced today the launch of Voice2Voice™, a consumer outreach program offering peer-to-peer support to primary immunodeficiency (PI) patients and caregivers. The program will offer assistance exclusively to new patients as they begin at-home use of Vivaglobin® (Immune Globulin Subcutaneous, Human), the first and only U.S. Food and Drug Administration-approved subcutaneous immunoglobulin (Ig) for treatment of patients with primary immunodeficiency.
More.
09 December 2008
CSL Behring Awards Second Round of LEAD Grants in Support of Patient Group Advocacy Efforts
CSL Behring, a global leader in the plasma-protein biotherapies industry, announces the awarding of five grants totaling more than $65,000 to patient advocacy organizations in the United States. These five grants represent the second round of semi-annual awards in the company's Local Empowerment for Advocacy Development (LEAD) program. To date, the company has awarded more than $150,000 in grants through the LEAD program.
More.
19 November 2008
CSL Behring Launches GameFaces™ Program at National Hemophilia Foundation Annual Meeting
CSL Behring announced today it launched the first challenge of GamesFaces™, a family-oriented online initiative for patients with hemophilia A, at the 60th Annual Meeting of the National Hemophilia Foundation (NHF). GameFaces is designed to encourage real-life physical activity through a series of three customized challenges based on the individual’s age, disease severity and current level of physical activity. Participants can now log on to the program website at www.HFSGameFaces.com, create their GameFaces character and begin the first challenge, which will run from today through January 10, 2009.
More.
30 September 2008
CSL Behring Initiating Next Round of LEAD Grants to Support Patient Advocacy Efforts
CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions.
More.
22 August 2008
CSL Behring’s Innovative HeliTraxSM System
Hemophilia A patients who use Helixate® FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progress in real time, thanks to the HeliTraxSM System, a state-of-the-art wireless Internet-based data management system recently introduced by CSL Behring.
More.